⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Figure S7 from Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients

Brooke Horowitch Daniel Y. Lee Min Ding Sandra Martínez-Morilla Thazin Nwe Aung Feriel Ouerghi Xueting Wang Wei Wei William Damsky Mario Sznol Harriet M. Kluger David L. Rimm Jeffrey J. Ishizuka

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplemental Figure 7: pSTAT1Y701, CD3, and driver mutation status in tumors based on combined STAT1 and PD-L1 status.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Horowitch et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522d96 https://doi.org/10.1158/1078-0432.27031813.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S3 from Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients2024
2Figure S4 from Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients2024
3Figure S5 from Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients2024
4Figure S8 from Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients2024
5Data from Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients2024

More related papers

Figure S6 from Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients2024
Tables S1 and S2 from Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients2024
Tables S1 and S2 from Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients2024